Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia (LINC-II): an open-label, randomised controlled...

Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence.  Li X, Langleben DD, Lynch KG, Wang GJ, Elman I, Wiers CE, Shi Z.  Front Psychiatry. 2023 Aug 2;14:12479...

Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone.  Marciuch A, Birkeland B, Benth JŠ, Solli KK, Tanum L, Mathisen I, Weimand B.  Heliyon. 2023 Jul 5;9(7):e17516. doi: 10.1016/j.hel...

Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.  Wang L, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R.  J Clin Psychol. 2023 Aug 16. doi...

Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder.  Shi Z, Li X, Kampman KM, Childress AR, Wiers CE, Langleben DD.  J Clin Psychia...

Using naltrexone to validate a human laboratory test system to screen new medications for alcoholism (TESMA)- a randomized clinical trial.  Spreer M, Grählert X, Klut IM, Al Hamdan F, Sommer WH, Plawecki MH, O'Connor S, Böttcher M, Sauer C, ...